

Anticonvulsants (8)

Point-of-Sale (POS) edits are safety limitations that are automatically verified through computer programming at the time that a prescription claim is submitted at the pharmacy. These edits can be applied to *any* medication, whether or not it is listed in the Preferred Drug List / Non-Preferred Drug List (PDL/NPDL). The first section of this document is organized to follow the order of the therapeutic classes in the PDL/NPDL and explains the POS edits for those medications.

POS Abbreviations

AL – Age Limit	DD – Drug-Drug Interaction	MD – Maximum Dose Limit	TD - Therapeutic Duplication
BH – Behavioral Health Clinical Authorization for Children Younger than 7 Years of Age	DS Maximum Days’ Supply Allowed	PR – Enrollment in a Physician-Supervised Program Required	UN – Drug Use Not Warranted
BY – Diagnosis Codes Bypass Some Requirements	DT – Duration of Therapy Limit	PU – Prior Use of Other Medication is Required	X – Prescriber Must Have ‘X’ DEA Number
CL – Additional Clinical Information is Required	DX – Diagnosis Code Requirement	QL – Quantity Limit	YQ – Yearly Quantity Limit
CU – Concurrent Use with Other Medication is Restricted	ER – Early Refill	RX – Specific Prescription Requirement	

Pharmacy Prior Authorization Phone Numbers for MCOs and FFS

Aetna Better Health of Louisiana **1-855-242-0802**

AmeriHealth Caritas Louisiana **1-800-684-5502**

Fee-for-Service (FFS) Louisiana Legacy Medicaid **1-866-730-4357**

Healthy Blue **1-844-521-6942**

Louisiana Healthcare Connections **1-888-929-3790**

UnitedHealthcare **1-800-310-6826**

Anticonvulsants (8)

POS Edits			
AL – Fycompa® (perampanel) is limited to use in recipients who are at least 4 years old. <i>The age limit may be overridden at the pharmacy POS after the dispensing pharmacist consults with the prescriber to verify necessity of prescribing perampanel for a child younger than 4 years of age.</i>			
BH – Additional behavioral-health related clinical information (trial of behavioral therapy, etc.) is required for carbamazepine and clonazepam when requested for a behavioral health diagnosis for recipients who are younger than 7 years of age.			
BY – Pharmacy claims for selected anxiolytics, when submitted with a seizure-related diagnosis code will bypass the behavioral-health clinical authorization requirement, the restriction on concurrent use with opioids, and quantity limits (see Anticonvulsant Quantity Limits <i>with</i> Bypass Diagnosis Codes chart below).			
CU – Benzodiazepines are monitored at POS for concurrent use with opioids and buprenorphine-containing products. <ul style="list-style-type: none">- Concurrent pharmacy claims for benzodiazepines and buprenorphine will deny.- Incoming benzodiazepine pharmacy claims will deny when the recipient has an active prescription (a prescription in which the days’ supply has not expired) for an opioid.			
PU – For Epidiolex®, the pharmacy POS system verifies that there has been a paid claim in the previous 365 days for AT LEAST TWO of the following agents [<u>brand/generic or preferred/non-preferred</u>]: <ul style="list-style-type: none">- <u>Clobazam</u>- <u>Felbamate</u>- <u>Lamotrigine</u>- <u>Levetiracetam</u>- <u>Rufinamide</u>- <u>Topiramate</u>- <u>Valproate derivatives</u>			
QL – Solid oral dosage forms of clonazepam have a quantity limit when used for a non-seizure-related diagnosis. Pharmacy claims for clonazepam that are submitted with a seizure-related diagnosis will bypass the quantity limit.	Anticonvulsant Quantity Limits <i>with</i> Bypass Diagnosis Codes		
	Generic (Brand Example)		Quantity Limit
	Clonazepam (Klonopin®)		90 units in 30 days
	Seizure-Related Diagnosis Codes Will Bypass Behavioral Health Clinical Authorization Requirement or Concurrent Use with Opioids or Applicable Quantity Limits	Epilepsy, Seizures	G40.*
		Convulsions in Newborn	P90
		Other Convulsions	R56.*
TD – Clonazepam is monitored at the pharmacy POS for duplication of therapy with other benzodiazepines and with oxybate (Xyrem®).			

Revision	Date
Created POS Document	November 2020
<u>Added previous-use requirement for Epidiolex®</u>	<u>December 2020</u>